利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.033 秒)

    Pharmaceutical composition for oral use with improved absorption
    3.
    发明授权
    Pharmaceutical composition for oral use with improved absorption 有权
    用于口服使用的药物组合物具有改善的吸收

    公开(公告)号：US07871644B2

    公开(公告)日：2011-01-18

    申请号：US10949114

    申请日：2004-09-10

    申请人： Shunsuke Watanabe ,  Shigeo Takemura ,  Yuuki Tsutsui ,  Himoru Kondo ,  Kiyo Nakanishi ,  Kazuhiro Sako ,  Toyohiro Sawada

    发明人： Shunsuke Watanabe ,  Shigeo Takemura ,  Yuuki Tsutsui ,  Himoru Kondo ,  Kiyo Nakanishi ,  Kazuhiro Sako ,  Toyohiro Sawada

    IPC分类号： A61K9/22 ,  A61K9/20 ,  A61K9/28 ,  A61K9/32 ,  A61K9/48

    CPC分类号： A61K9/2027 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2893 ,  A61K31/65 ,  A61K31/663 ,  A61K47/12 ,  A61K47/32

    摘要： The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.

    摘要翻译： 本发明提供了具有改善吸收性的口服用药物组合物，其包括药物，甲基丙烯酸氨基烷基酯共聚物E和酸性物质，并且通过使所述3种组分一起并将至少该聚合物与该酸性物质均匀混合而获得， 通过使用该药物组合物改善口服吸收。 此外，本发明提供了改善口服吸收的药剂，其增加存在于该膜的表面上的消化道粘膜和/或粘膜层的药物通透性，其活性成分是甲基丙烯酸氨基烷基酯共聚物E.另外，本发明 提出了通过增加分泌在该粘膜上的消化道粘膜和/或粘膜层的药物通透性来改善吸收的口服剂，其有效成分是甲基丙烯酸氨基烷基酯共聚物E.

    PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
    4.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION 审中-公开
    用于口服管理的药物组合物

    公开(公告)号：US20100144711A1

    公开(公告)日：2010-06-10

    申请号：US12568342

    申请日：2009-09-28

    申请人： Shinsuke Oba ,  Takehiko Yasuji ,  Tadashi Hakomori ,  Kazuhiro Sako

    发明人： Shinsuke Oba ,  Takehiko Yasuji ,  Tadashi Hakomori ,  Kazuhiro Sako

    IPC分类号： A61K31/551 ,  A61P7/02

    CPC分类号： A61K31/551 ,  A61K9/2018 ,  A61K9/2054

    摘要： A pharmaceutical composition for oral administration, comprising 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof, and hydroxypropyl cellulose having a viscosity of approximately 6 mPa·S (inclusive) to approximately 150 mPa·S (exclusive) in a 2% aqueous solution at 20° C., or a viscosity of 75 mPa·S (inclusive) to 400 mPa·S (inclusive) in a 5% aqueous solution at 25° C., and a process of manufacturing the pharmaceutical composition for oral administration are disclosed.

    摘要翻译： 一种用于口服给药的药物组合物，包含3-羟基-N1-（4-甲氧基苯甲酰基）-N2- [4-（4-甲基-1,4-二氮杂环庚烷-1-基）苯甲酰] -1,2-苯二胺或 其药学上可接受的盐和在20℃的2％水溶液中粘度为约6mPa·S（含）至约150mPa·S（独占）的羟丙基纤维素，或粘度为75mPa·S（ 包含）至25℃下的5％水溶液中的400mPa·S（含），并且公开了用于口服给药的药物组合物的制造方法。

    Stable pharmaceutical composition for oral use
    6.
    发明授权
    Stable pharmaceutical composition for oral use 有权
    稳定的口服药物组合物

    公开(公告)号：US06562375B1

    公开(公告)日：2003-05-13

    申请号：US09629405

    申请日：2000-08-01

    申请人： Kazuhiro Sako ,  Toyohiro Sawada ,  Keiichi Yoshihara ,  Tatsunobu Yoshioka ,  Shunsuke Watanabe

    发明人： Kazuhiro Sako ,  Toyohiro Sawada ,  Keiichi Yoshihara ,  Tatsunobu Yoshioka ,  Shunsuke Watanabe

    IPC分类号： A61K914

    CPC分类号： A61K9/2031 ,  A61K9/2009

    摘要： The present invention is to provide a stable pharmaceutical composition for oral use and preparation thereof in which changes are prevented in drug release at stored even under the exposure to light by adding yellow ferric oxide and/or red ferric oxide in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The present invention is to further provide a method for preventing changes in drug release at stored under the exposure to light in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The quality assurance period of the product can be prolonged and the product value can be improved by the present invention.

    摘要翻译： 本发明提供一种用于口服使用的稳定药物组合物及其制备方法，其中通过在基质型缓释中加入黄色氧化铁和/或红色氧化铁，甚至在暴露于光下时，在药物释放期间可以防止变化 含有药物，亲水性碱和聚环氧乙烷的制剂。 本发明进一步提供一种在含有药物，亲水性碱和聚环氧乙烷的基质型缓释制剂中防止在暴露于光下储存的药物释放变化的方法。 通过本发明可以延长产品的质量保证期并提高产品价值。

    METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE
    7.
    发明申请
    METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE 审中-公开
    制造用于控制释放活性物质的药物组合物的方法

    公开(公告)号：US20090035372A1

    公开(公告)日：2009-02-05

    申请号：US12244719

    申请日：2008-10-02

    申请人： Akio Sugihara ,  Kazuhiro Sako ,  Toyohiro Sawada

    发明人： Akio Sugihara ,  Kazuhiro Sako ,  Toyohiro Sawada

    IPC分类号： A61K9/22 ,  A61K47/34 ,  A61K47/32 ,  A61K31/18

    CPC分类号： A61K31/18 ,  A61K9/1641 ,  A61K9/2031

    摘要： The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product.A controlled-release pharmaceutical composition with good uniformity of content can be presented by using powder particles of polyethylene oxide with powder properties suitable for tableting, which is obtained by uniform dispersion of the specific size controlling agent for polyethylene oxide of the present invention.

    摘要翻译： 本发明涉及含有药物，分子量为200万以上的聚环氧乙烷和聚环氧乙烷的特定尺寸控制剂（具有适当的可塑性和结合力的物质）的尺寸的产品，其中至少上述 上述特定尺寸控制剂均匀地分散在上述聚环氧乙烷中，含有这种尺寸的产品的控释药物组合物，以及含有这种尺寸的产品的控释药物组合物的制造方法。 通过使用本发明的聚环氧乙烷特定尺寸控制剂的均匀分散得到的适合于压片的粉末性能的聚环氧乙烷粉末颗粒，可以提供具有良好的含量均匀性的控释药物组合物。

    Method for improving adsorption of a drug from ethylene oxide derivative
    8.
    发明授权
    Method for improving adsorption of a drug from ethylene oxide derivative 失效
    改善环氧乙烷衍生物吸收药物的方法

    公开(公告)号：US07153524B2

    公开(公告)日：2006-12-26

    申请号：US10672398

    申请日：2003-09-26

    申请人： Keiichi Yoshihara ,  Kazuhiro Sako

    发明人： Keiichi Yoshihara ,  Kazuhiro Sako

    IPC分类号： A61K9/14 ,  A61K31/47

    CPC分类号： A61K47/10 ,  A61K9/0065

    摘要： The present invention relates to a method for improving adsorption on the gastrointestinal mucous layers of one or more selected from polyethylene glycol, polyethylene oxide, and polyoxyethylene polypropylene copolymer wherein the average number of repeating oxyethylene units of one ethylene oxide chain length is 17 or greater. It is possible to enhance pharmacological effects by using the present invention with drugs that have anti-H. pylori activity.

    摘要翻译： 本发明涉及一种改善一个或多个选自聚乙二醇，聚环氧乙烷和聚氧乙烯聚丙烯共聚物中的一种或多种吸附的方法，其中一个环氧乙烷链长度的重复氧化乙烯单元的平均数为17或更大。 本发明可以通过具有抗-H的药物来提高药理作用。 幽门螺杆菌活动。

    Hydrogel-forming sustained-release preparation
    10.
    发明授权
    Hydrogel-forming sustained-release preparation 失效
    水凝胶形成持续释放制剂

    公开(公告)号：US06436441B1

    公开(公告)日：2002-08-20

    申请号：US08403752

    申请日：1995-03-20

    申请人： Kazuhiro Sako ,  Hiroshi Nakashima ,  Toyohiro Sawada ,  Akira Okada ,  Muneo Fukui

    发明人： Kazuhiro Sako ,  Hiroshi Nakashima ,  Toyohiro Sawada ,  Akira Okada ,  Muneo Fukui

    IPC分类号： A61K922

    CPC分类号： A61K9/2054 ,  A61K9/2018 ,  A61K9/2031

    摘要： The invention provides a hydrogel-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogel-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon. By the preparation of the invention, the drug is efficiently released and absorbed even in the colon so that a steady and sustained release effect can be achieved.

    摘要翻译： 本发明提供一种水凝胶型持续释放制剂，其包含（1）至少一种药物，（2）确保水渗入制剂核心的添加剂，和（3）水凝胶形成聚合物，其中所述制剂 能够在上消化道（如胃和小肠）停留期间发生基本上完全的凝胶化，并且能够在包括结肠的下消化道中释放药物。通过本发明的制备，药物被有效地释放和吸收 即使在结肠中也能达到稳定和持续释放的效果。